Advancements in Biomarker Assays and Stem Cell Therapies

Share this:
Published: 22 Jun 2018

The Genetic Technology TechVision Opportunity Engine (TOE) presents trends across biomarker assays and stem cell therapies. A blood test for traumatic brain injury, use of umbilical cord mesenchymal stem cells and adipose-derived mesenchymal stem cells for treatment of liver cirrhosis, and using mesenchymal stem cells for treatment of ulcerative colitis are profiled. The corresponding clinical trials scenario is also depicted. The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Biomarker assays, stem cell therapies, blood test, traumatic brain injury, umbilical cord mesenchymal stem cells, adipose-derived mesenchymal stem cells, mesenchymal stem cells, ulcerative colitis, liver cirrhosis

Tools

Features of this research

SUBSCRIPTIONS

Help Desk

Full list of offices


For more information and general enquiries, contact Frost & Sullivan near you.

North America
tel: +1.877.463.7678

Select a location near you..